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Background: Although the prognostic relevance of KRAS status in metastatic
colorectal cancer (CRC) depends on tumor laterality, this relationship is largely
unknown in non‐metastatic CRC.
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Methods: Patients who underwent resection for non‐metastatic CRC between 2000
and 2018 were identified from institutional databases at six academic tertiary
centers in Europe and Japan. The prognostic relevance of KRAS status in patients
with right‐sided (RS), left‐sided (LS), and rectal cancers was assessed.
Results: Of the 1093 eligible patients, 378 had right‐sided tumors and 715 had left‐
sided tumors. Among patients with RS tumors, the 5‐year overall (OS) and
recurrence‐free survival (RFS) for patients with KRASmut versus wild‐type tumors
was not shown to differ significantly (82.2% vs. 83.2% and 72.1% vs. 76.7%, re-
spectively, all p > .05). Among those with LS tumors, KRAS mutation was associated
with shorter 5‐year OS and RFS on both the univariable (OS: 79.4% vs. 86.1%,
p = .004; RFS: 68.8% vs. 77.3%, p = .005) and multivariable analysis (OS: HR: 1.52,
p = .019; RFS: HR: 1.32, p = .05).
Conclusions: KRAS mutation status was independently prognostic among patients
with LS tumors, but this association failed to reach statistical significance in RS and
rectal tumors. These findings confirm reports in metastatic CRC and underline the
possible biologic importance of tumor location.
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy
worldwide and accounts for approximately 10% of all new cancer
cases yearly.1 Kirsten rat sarcoma viral oncogene homolog (KRAS)
mutation is an early event in the carcinogenesis of CRC and occurs in
around 30%–40% of colon cancers.2 The prognostic role of KRAS
mutations in non‐metastatic CRC has been primarily studied using
pathologic material from large clinical trials that assessed the role of
chemotherapeutic agents as adjuvant treatment for resected CRC.
Although a number of reports failed to demonstrate that KRAS
mutation status was prognostic, larger and more adequately pow-
ered studies ultimately showed that KRAS mutation status is clearly
prognostic.3–7
Another variable that has recently emerged as an important
prognostic factor is tumor laterality (right vs. left). Earlier reports
had discrepant findings; for example, for early‐stage CRC cancers
(stages I–II), right‐sided disease was associated with superior survi-
val, whereas for late‐stage disease (stage III), left‐sided disease was
associated with improved survival.8–12 In contrast, others have found
that tumor laterality is not associated at all with survival in early‐
stage resected colon cancer.13 Nonetheless, in the largest study to
date, which included >1 million patients, Petrelli et al.14 reported
that left‐sided primary tumor location was associated with a sig-
nificantly reduced risk of death independent of stage.
A recent study by our group demonstrated that in metastatic
CRC, the prognostic relevance of KRAS status was contingent on
primary tumor laterality.15 Specifically, KRAS was prognostic only
among patients with left‐sided, metastatic CRC. Importantly, this
relationship is largely unknown in non‐metastatic CRC. Thus, we
undertook this study to investigate whether a similar interplay of
KRAS mutation status and tumor laterality exists in this specific
population.
2 | METHODS
2.1 | Study design, inclusion criteria, and
pertinent variables
Patients with non‐metastatic CRC (stages I–III) who were surgically
treated between January 2000 and December 2018 and with known
KRAS mutation status were retrospectively identified from institu-
tional databases at four academic tertiary centers in Europe and two
in Japan. Participating centers included Charite—University of
Berlin (Berlin, Germany), Erasmus Medical Center (Rotterdam,
Netherlands), Attiko Hospital (Athens, Greece), Hippokrateion
Hospital (Athens, Greece), Saitama Cancer Center (Saitama, Japan),
and Graduate School of Medical Sciences, Kumamoto University
(Kumamoto, Japan). Patients with unknown BRAF mutation status,
unknown microsatellite stability (MSI) status, double KRAS/BRAF
mutations, as well as those with unknown follow‐up were excluded
from the study cohort.
Data on demographics and clinical features, including age at the
time of diagnosis, sex, neoadjuvant systemic treatments (for those
with rectal tumors), primary tumor laterality, tumor category (T),
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nodal disease category, tumor grade, lymphovascular invasion (LVI),
vascular invasion, BRAF status, microsatellite instability (MSI‐H)
status, and adjuvant systemic treatments were collected. To maintain
consistency with previous studies, we defined primary tumors
located in the cecum, ascending colon, and transverse colon as right‐
sided tumors, and tumors located in the splenic flexure, descending
colon, sigmoid colon, and rectum as left‐sided tumors. Data on long‐
term outcomes including recurrence and overall survival status at
last follow‐up were collected.
2.2 | Statistical analysis
Categorical variables were described as totals and frequencies,
whereas numerical variables were presented as medians with in-
terquartile ranges (IQR). Continuous variables were compared
using the χ2 test while numerical variables were compared using
the Wilcoxon–Mann–Whitney or Kruskal–Wallis tests, as appro-
priate. RFS and OS were calculated from the date of surgery using
the Kaplan–Meier method, and differences in RFS and OS
were assessed with the Log‐rank test. Cox proportional hazards
regression models were used to identify potential predictors of
survival. Variables that were found to have a statistically sig-
nificant association with outcomes on the univariable analysis
(p < .05) were included in the multivariable analysis. The propor-
tional assumption of the Cox model was tested using the
Schoenfeld residuals test, and the model was stratified based on
variables that did not meet the proportional assumption for the
Cox model. Interaction between variables was also tested and
included in the final model. Statistical analysis was performed
using Stata/MP version 13.1 (StataCorp).
3 | RESULTS
3.1 | Characteristics of patients with right‐ versus
left‐sided tumors
A flow chart that demonstrates cohort selection is illustrated in
Figure 1. A total of 1093 patients met the inclusion criteria. Of those,
378 had right‐sided (RS) tumors and 715 had left‐sided (LS) tumors.
Among the latter, there were 251 patients with rectal tumors.
Detailed demographic, clinicopathologic, and genetic data of patients
who had RS versus LS CRC and “truly left” versus rectal tumors are
summarized in Tables S1 and S2, respectively.
Patients with RS tumors were more likely to be older (68 vs. 64
years old, p < .001) and female (50.9% vs. 39%, p < .001). As ex-
pected, they were also more likely to have BRAF mutated tumors
(13.5% vs. 1.8%, p < .001) and MSI‐H tumors (24.9% vs. 3.9%,
p < .001). In addition, these patients were more likely to have high
grade tumors (11.9% vs. 6.3%, p = .02). Lastly, patients with RS
tumors were less likely to receive adjuvant chemotherapy (38.6%
vs. 45.3%, p = .03).
3.2 | Characteristics of patients with RS KRASmut
versus wild‐type tumors
Of the 378 patients with RS tumors, 261 (69%) had wild‐type tumors
and 117 (31%) had KRASmut tumors. Detailed demographic, clin-
icopathologic, and genetic data of patients who had RS versus LS
CRC stratified by KRAS status are summarized in Table 1.
Among patients who had RS tumors, the demographic and clin-
icopathologic characteristics did not differ by KRAS status. In regard
to genetic characteristics, patients with wild‐type tumors were more
likely to have MSI‐H (31.4% vs. 10.3%, p < .001) and BRAFmut tu-
mors (19.5% vs. 0%, p < .001). For treatment variables, patients with
wild‐type tumors were less likely to receive adjuvant chemotherapy
(34.5% vs. 47.9%, p = .014).
3.3 | Characteristics of patients with LS KRASmut
versus wild‐type tumors
Of the 715 patients with LS tumors, 488 (68.2%) had wild‐type
tumors and 227 (31.8%) had KRASmut tumors. Detailed demo-
graphic, clinicopathologic, and genetic data of patients who had LS
versus RS CRC stratified by KRAS status are summarized in Table 1.
Among patients who had LS tumors, patients with wild‐type tumors
were more likely to be male (64.6% vs. 53.3%, p = .004) and patients
with KRASmut tumors were more likely to have lymphovascular in-
vasion (58% vs. 48.4%, p = .02). In regard to genetic characteristics,
patients with wild‐type tumors were less likely to have MSI‐H (2.9%
vs. 6.2%, p = .034) but more likely to have BRAFmut tumors (2.7% vs.
0%, p < .001).
F IGURE 1 Flow chart of the study cohort [Color figure can be
viewed at wileyonlinelibrary.com]
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3.4 | Main analyses
3.4.1 | OS in the entire cohort and in RS versus
LS CRC
With a median follow‐up of 73.6 months, 237 patients (21.7%) died.
After CRC resection, 1‐, 3‐, and 5‐year OS of the entire cohort were
89.9%, 83.6%, and 72.7%, respectively. Factors that were in-
dependently associated with survival in the entire cohort are sum-
marized in Table S3.
Among patients with RS CRC, KRAS mutation was not asso-
ciated with OS on either univariable or multivariable analysis
(Table 2). The 5‐year OS for patients with RS KRASmut versus wild‐
type tumors was 82.2% versus 83.2% (p = .43), respectively
(Figure 2A). The factors that were independently associated with
worse survival were age (HR: 1.05; p < .001) and N category (HR:
1.83; p = .03).
Among patients with LS CRC, KRAS mutation was associated
with OS on both univariable (5‐year OS: KRASmut vs. wild‐type;
79.4% vs. 86.1%, respectively; p = .004; Figure 2B) and multivariable
analysis (HR: 1.52; p = .019; Table 2). The other factors that were
independently associated with worse survival were age (HR: 1.05;
p < .001), male sex (HR: 2.06; p < .001), advanced T category (HR:
1.69; p = .045), and lymphovascular invasion (HR: 1.72; p = .019).
TABLE 1 Patient characteristics stratified by primary tumor side and KRAS mutation status
Right sided Left‐sided
Characteristic All patients KRAS‐wt KRAS‐mut p KRAS‐wt KRAS‐mut p
No. of patients 261 117 488 227
Patient characteristics
Age (years), median (IQR) 68 (61–74) 67 (60–74) .59 64 (58–71) 64 (57–71) .82
Sex
Male 621 (56.9) 125 (48.1) 60 (51.3) .57 315 (64.6) 121 (53.3) .004
Female 471 (43.1) 135 (51.9) 57 (48.7) 173 (35.4) 106 (46.7)
Primary tumor characteristics
T category
T1 83 (7.6) 20 (7.7) 10 (8.6) .14 32 (6.6) 21 (9.3) .06
T2 230 (21.1) 55 (21.1) 13 (11.1) 123 (25.2) 39 (17.2)
T3 677 (61.9) 163 (62.4) 82 (70.1) 291 (59.6) 141 (62.1)
T4 103 (9.4) 23 (8.8) 12 (10.3) 42 (8.6) 26 (11.4)
Stage combination
T1–T2 313 (28.6) 75 (28.7) 23 (19.7) .06 155 (31.8) 60 (26.4) .15
T3–T4 780 (71.4) 186 (71.3) 94 (80.3) 333 (68.2) 167 (73.6)
Primary tumor nodal metastases 411 (37.6) 86 (33.0) 49 (41.9) .09 185 (37.9) 91 (40.1) .58
Tumor grade (n = 836)
Low 85 (10.2) 15 (10.5) 10 (9.9) .90 36 (9.7) 24 (11.0) .61
Intermediate 685 (81.9) 110 (76.9) 80 (79.2) 316 (84.7) 179 (81.7)
High 66 (7.9) 18 (12.6) 11 (10.9) 21 (5.6) 16 (7.3)
Lymphovascular invasion (n = 838) 447 (53.3) 84 (58.7) 55 (53.9) .45 181 (48.4) 127 (58.0) .02
Vein invasion (n = 838) 544 (64.9) 103 (72.0) 63 (61.8) .09 235 (62.8) 143 (65.3) .54
Genetic characteristics
MSI status 122 (11.2) 82 (31.4) 12 (10.3) <.001 14 (2.9) 14 (6.2) .034
BRAF status 64 (5.9) 51 (19.5) 0 <.001 13 (2.7) 0 .013
Adjuvant chemotherapy 470 (43.0) 90 (34.5) 56 (47.9) .014 222 (45.5) 102 (44.9) .88
Total
5FU‐based regimen 388 (71.9) 45 (50.0) 44 (78.6) .002 157 (70.7) 92 (90.2) <.001
Oxaliplatin‐based regimen 33 (7.0) 5 (5.6) 4 (7.1) 17 (7.7) 7 (6.9)
Capecitabine 3 (0.7) 2 (2.2) 1 (1.8) – –
Other/unknown 99 (20.4) 38 (42.2) 7 (12.5) 48 (21.6) 3 (2.9)
Note: Bold values are statistically significant at p < .05.
Abbreviations: IQR, interquartile range; mut, mutant type, wt, wild type.
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3.4.2 | RFS in RS versus LS CRC
Similar to OS, KRAS mutation was prognostic only in LS and not RS
tumors for RFS. Among those with RS tumors, 5‐year RFS for
KRASmut versus wild‐type was 72.1% versus 76.7% (p = .215), re-
spectively (Figure 3A). In contrast, among patients with LS tumors,
5‐year RFS for KRASmut versus wild‐type was 68.8% versus 77.3%
(p = .005), respectively (Figure 3B).
The only factor that was independently associated with worse
RFS among patients with RS tumors was N category (HR: 2.55;
p = .001; Table 3). Among those with LS tumors, male sex (HR: 1.65;
p = .012), advanced T category (HR: 2.49; p = .001), and KRAS
TABLE 2 Univariable and multivariable overall survival analysis stratified by primary tumor location
Right sided Left sided
Univariate Multivariate Univariate Multivariate
Characteristic HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.04 (1.02–1.07) .001 1.05 (1.02–1.09) <.001 1.05 (1.03–1.07) <.001 1.05 (1.03–1.07) <.001
Male sex 1.28 (0.84–1.96) .26 – 2.07 (1.43–3.00) <.001 2.06 (1.38–3.07) <.001
T category
T1–T2 Ref Ref Ref
T3–T4 1.66 (0.96–2.84) .068 – 2.74 (1.74–4.31) <.001 1.69 (1.01–2.83) .045
Primary tumor nodal metastases 1.93 (1.26–2.93) .002 1.83 (1.06–3.15) .03 1.97 (1.43–2.72) <.001 1.24 (0.85–1.80) .26
Tumor grade
Low Ref Ref
Intermediate 1.33 (0.53–3.35) .54 – 1.19 (0.64–2.21) .58
High 1.32 (0.38–4.57) .66 – 1.81 (0.77–4.27) .17
Lymphovascular invasion 1.99 (1.11–3.60) .021 1.78 (0.95–3.32) .07 2.91 (1.95–4.34) <.001
Vein invasion 2.06 (1.08–3.99) .03 1.88 (0.96–3.65) .06 2.51 (1.64–3.86) <.001 1.72 (1.09–2.72) .019
KRAS mutation 1.19 (0.77–1.86) .43 – 1.61 (1.16–2.22) .004 1.52 (1.07–2.15) .019
MSI mutation 1.15 (0.71–1.85) .56 – 0.63 (0.23–1.71) .37
BRAF mutation 1.32 (0.76–2.31) .32 – 1.85 (0.69–5.01) .22
Adjuvant chemotherapy 1.09 (0.70–1.68) .71 – 0.88 (0.64–1.22) .45
Note: Bold values are statistically significant at p < .05.
Abbreviations: HR, hazard ratio; MSI, microsatellite instability.
F IGURE 2 (A and B) Overall survival of patients with right‐ and left‐sided tumors stratified by KRAS mutation status
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mutation (HR: 1.43; p = .05) were independently associated with
worse RFS (Table 3).
3.4.3 | Subgroup analyses
Given that KRAS mutation status is prognostic in left‐ but not right‐
sided non‐metastatic CRC, we explored this finding by conducting a
series of sensitivity analyses.
1. Subanalysis of OS and RFS in patients with RS versus LS tumors after
excluding patients with BRAFmut tumors
Similar to the main analysis, among patients with RS CRC, KRAS
mutation was not associated with OS on both univariable and
multivariable analysis. The 5‐year OS for patients with RS
KRASmut versus wild‐type tumors was 82.2% versus 83.7%
(p = .256), respectively. In contrast, among patients with LS CRC,
KRAS mutation was associated with OS on both univariable
(5‐year OS: KRASmut vs. wild‐type; 79.4% vs. 86.4%, respectively;
p = .003) and multivariable analyses (HR: 1.57; p = .01).
In addition, KRAS mutation was an independent prognostic factor
of RFS only for patients with LS tumors (HR: 1.38; p = .06),
whereas for patients with RS tumors, KRAS mutation was not
prognostic even on univariable analysis (HR: 1.34; p = .18).
2. Sub‐analysis of OS and RFS in patients with RS versus LS tumors after
excluding patients with MSI‐H tumors
Similar to the main analysis, among patients with RS CRC, KRAS
mutation was not associated with OS on both univariable and
multivariable analysis. The 5‐year OS for patients with RS
KRASmut versus wild‐type tumors was 84.3% versus 82.6%, re-
spectively. Among patients with LS CRC, KRAS mutation was
associated with OS on both univariable (5‐year OS: KRASmut vs.
wild‐type; 79.4% vs. 85.7%, respectively; p = .005) and multi-
variable analyses (HR: 1.51; p = .02). In addition, KRAS mutation
was an independent prognostic factor of RFS only for patients
with LS tumors (HR: 1.51; p = .03), whereas for patients with RS
tumors, KRAS mutation was not prognostic even on univariable
analysis (HR: 1.06; p = .78).
3. Sub‐analysis of OS and RFS in patients with RS versus LS tumors after
excluding patients who underwent surgery before 2005
Similar to the main analysis, among patients with RS CRC, KRAS
mutation was not associated with OS on both univariable and
multivariable analyses. The 5‐year OS for patients with RS
KRASmut versus wild‐type tumors was 80.3% versus 81.9%
(p = .553), respectively. In contrast, although KRAS mutation was
not an independent factor of OS for patients with LS tumors
(HR: 1.46; p = .24), it was significantly associated with worse OS
on univariable analysis (78.8% vs. 87.1% for KRASmut and wild‐
type, respectively; p = .045). Among patients with RS tumors,
KRAS mutation was not prognostic even on univariable analysis
(HR: 1.21; p = .55). Similarly, KRAS mutation was not an in-
dependent prognostic factor of RFS for patients with LS tumors
(HR: 1.48; p = .078).
4. Subanalysis of OS and RFS in patients with “true” left‐sided versus
rectal tumors
KRAS mutation was prognostic only for patients with “true” LS but
not rectal tumors. Specifically, among the former, 5‐year OS for
KRASmut versus wild‐type was 79.7% versus 87.6% (p = .005), re-
spectively (Figure 4A). Among the latter, 5‐year OS for KRASmut
versus wild‐type was 78.9% versus 83.2%, respectively, but failed to
reach statistical significance (p = .342; Figure 4B). On multivariable
analysis, KRAS mutation was an independent prognostic factor for
patients with “true” LS tumors (HR: 1.91; p = .006), whereas for
F IGURE 3 (A and B) Recurrence‐free survival of patients with right‐ and left‐sided tumors stratified by KRAS mutation status
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patients with rectal tumors, KRAS mutation was not prognostic even
on univariable analysis (HR: 1.29; p = .34).
Similarly, KRAS mutation was an independent prognostic factor
of RFS for patients with “true” LS tumors (HR: 1.68; p = .02;
Figure 5A), whereas for patients with rectal tumors, KRAS mutation
was not prognostic even on univariable analysis (HR: 1.25; p = .32;
Figure 5B).
4 | DISCUSSION
In this study, we utilized a double PTL and KRAS mutation status
stratification to analyze survival outcomes of 1093 patients from six
international academic centers who underwent resection for non‐
metastatic CRC. To our knowledge, this is the first study to examine
the interplay of these factors in patients with non‐metastatic CRC.
TABLE 3 Univariable and multivariable recurrence free survival analysis stratified by primary tumor location
Right sided Left sided
Univariate Multivariate Univariate Multivariate
Characteristic HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.01 (0.99–1.03) .31 1.04 (1.02–1.05) <.001 –a
Male sex 1.19 (0.80–1.77) .38 1.66 (1.23–2.25) <.001 1.65 (1.11–2.45) .012
T category
T1–T2 Ref Ref
T3–T4 1.91 (1.13–3.22) .015 1.68 (0.87–3.22) 0.12 3.35 (2.24–5.03) <.001 2.49 (1.42–4.37) .001
Primary tumor nodal metastases 2.62 (1.77–3.89) <.001 2.55 (1.45–4.47) 0.001 2.19 (1.66–2.88) <.001 1.47 (0.99–2.16) .05
Tumor grade
Low Ref Ref
Intermediate 0.83 (0.41–1.67) .60 1.25 (0.73–2.12) .41 –
High 1.31 (0.54–3.15) .55 2.39 (1.18–4.83) .016 –a
Lymphovascular invasion 1.78 (1.09–2.92) .02 1.15 (0.67–1.97) 0.61 2.74 (1.97–3.81) <.001 1.90 (1.24–2.91) .003
Vein invasion 1.62 (0.96–2.76) .07 2.63 (1.83–3.80) <.001 1.50 (0.96–2.36) .08
KRAS mutation 1.29 (0.86–1.95) .22 1.49 (1.13–1.98) .005 1.43 (0.99–2.07) .05
MSI mutation 0.48 (0.27–0.84) .01 0.99 (0.53–1.87) 0.99 0.55 (0.23–1.34) .19
BRAF mutation 1.04 (0.59–1.82) .90 1.98 (0.87–4.46) .09
Adjuvant chemotherapy 1.79 (1.21–2.66) .004 0.84 (0.50–1.43) 0.52 1.25 (0.95–1.64) .11
Note: Bold values are statistically significant at p < .05.
aDid not meet the proportional assumption for Cox model stratified based on the variable.
F IGURE 4 (A and B) Overall survival of patients with “true” left and rectal tumors stratified by KRAS mutation status
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The main finding of this study is that KRAS mutation status was
independently prognostic among patients with LS tumors, but this
association was far less pronounced and failed to reach statistical
significance among patients with RS tumors. Several sensitivity
analyses confirmed this finding. The second finding of the study is
that when left‐sided tumors were divided into “truly” left and rectal
tumors, the prognostic relevance of KRAS status was even more
pronounced in those with “truly” left tumors, whereas the prognostic
relevance of KRAS failed to reach statistical significance among pa-
tients with rectal tumors.
The main finding of this study has been previously corroborated
by Sasaki et al.,15 albeit in patients with metastatic CRC. Specifically,
they found that KRAS was prognostic only in patients with left‐sided
primary tumors but not in those with right‐sided tumors. Similar to
the study by Sasaki et al., the difference in survival between LS/
KRASmut versus LS/KRASwt (79.4% vs. 86.1%, respectively) stem-
med from both a decrease in survival of patients with left‐sided
KRASmut versus right‐sided KRASmut tumors (79.4% vs. 82.2%,
respectively), as well as improved survival of patients with left‐sided
wild‐type versus right‐sided wild‐type tumors (86.1% vs. 83.2%, re-
spectively). Of note, although the magnitude of the differences be-
tween LS and RS KRASmut (2.8%) and RS and LS KRASwt (2.9%) was
too small to be significant despite the numerical trend, the sum of the
two (5.7%) was significant. Regarding the decreased survival of pa-
tients with LS/KRASmut compared to RS/KRASmut, it is possible that
a higher rate of LS TP53 mutations, as noted by Loree et al.,13 may
accentuate the effect of LS KRAS mutations. This speculation stems
from a recent study by Datta et al.17 who demonstrated that in
metastatic CRC, KRAS is not prognostic without a co‐existing TP53
mutation.
To confirm the primary findings, we performed several sensi-
tivity analyses. First, we analyzed outcomes after excluding patients
with BRAF mutations, as it is a strong negative prognostic factor that
is more frequently encountered in RS disease. Theoretically, de-
creased survival of KRASwt patients with BRAF mutations may
narrow the survival gap between these patients and those with
KRASmut tumors. As expected, patients with right‐sided KRASwt
tumors were more likely to have BRAF mutations compared to their
left‐sided counterparts (19.5% vs. 2.7%). We excluded these patients
from the pool and re‐analyzed the data. The main finding remained
unchanged; KRAS was still not prognostic among patients with
RS tumors.
Next, we analyzed outcomes after excluding patients with MSI‐H
tumors, which is a strong favorable prognostic factor that is more
frequent in RS disease and can affect survival of RS wild‐type and
KRASmut patients.18 Indeed, MSI‐H was more prevalent in RS
tumors (24.9 vs. 3.9%). After excluding these patients from analysis,
the 5‐year OS for patients with RS KRASmut improved while that of
patients with wild‐type tumors worsened. Importantly, the main
finding remained unchanged; KRAS was not prognostic among
patients with RS tumors.
Given that regimens containing oxaliplatin and irinotecan be-
came popular after 2005, we also sought to validate the primary
finding of the study in the subcohort of patients who were treated in
the era of modern chemotherapy. When we excluded patients who
underwent surgery before 2005, the strong association with OS
deteriorated to a borderline significant association present only in
univariable analysis and disappeared completely for RFS. This may
relate to lower power, as well as the fact that modern chemotherapy
improved outcomes in stage III CRC, making it even more challenging
to detect a difference.
Although the binary stratification of tumor laterality as right
versus left seems straightforward, it may in reality be an over-
simplification. Almost all studies to date on the prognostic role of
tumor laterality have included transverse colon in the right side and
rectum in the left side. However, in a seminal study, Loree et al.16
F IGURE 5 (A and B) Recurrence‐free survival of patients with “true” left and rectal tumors stratified by KRAS mutation status
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demonstrated that the sigmoid‐rectal region is distinct from other
left‐sided locations. The division of left‐sided tumors to “truly” left
and rectal tumors not only confirmed the main result of the study,
but also revealed a new finding. Specifically, although a numerical
trend was apparent (5‐year OS for KRASmut vs. wild‐type was 78.9%
vs. 83.2%), the prognostic relevance of KRAS mutation status failed
to reach statistical significance among patients with rectal tumors.
Even if decreased statistical power partially contributed to this
finding, it was obvious that the prognostic relevance of KRAS status
was more pronounced among patients with “truly” left‐sided tumors
(5‐year OS for KRASmut vs. wild‐type was 79.7% vs. 87.6%). Our
findings are in line with a recent report by Amini et al.19 regarding
patients with metastatic CRC, which demonstrated that mutKRAS
status was independently associated with worse outcomes in
patients with CRLM arising from colon but not rectal cancer.
The results of the study should be interpreted with caution
given its retrospective design. Moreover, the study was limited by
the lack of pertinent information on other somatic mutations aside
from KRAS, BRAF, and MSI status. The inclusion of several in-
stitutions may have added heterogeneity to the study but in turn
adds to the generalizability of our findings. Although the cohort
was relatively large, some comparisons, in particular that for rectal
tumors, may have limited statistical power. Lastly, detailed data on
the systematic treatments (i.e., chemotherapy and radiotherapy)
were lacking.
5 | CONCLUSIONS
Ultimately, it appears that there is a continuum of prognostic re-
levance of KRAS mutation status in non‐metastatic and metastatic
CRC; the prognostic relevance of KRAS status appears to be con-
tingent on primary tumor laterality in both settings. In LS tumors, the
presence of KRAS mutation resulted in a greater proportional de-
crease in survival from a better baseline prognosis, ultimately leading
to a larger discrepancy in outcomes and a clear prognostic role for
KRAS mutation status. The prognostic impact of KRAS mutation
status was far less pronounced and failed to reach statistical sig-
nificance among patients with RS and rectal tumors. The latter
suggests that rectal tumors should not be grouped with left‐sided
tumors, contrary to current practice. The p53 mutation, which is
more prevalent in LS tumors, may have contributed to the greater
proportional decrease in survival of patients with LS KRASmut
tumors. Future studies, preferably employing NGS techniques, may
validate this hypothesis.
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